Summary: The development of methods for production of a radiotracer for use in human studies with positron emission tomography (PET) is often a time-consuming process of optimizing radiolabelling yields and handling procedures. Sometimes the radiotracer is not the original drug, but rather a derivative with unknown in vivo phar macological properties. We have developed a fast and simple method of testing putative new PET tracers in vivo in small animals. The procedure has been validated in rats with different PET tracers with known kinetic and phar macological properties ([2-'SF]2-fluoro-2-deoxY-D glucose, [N-methyl-"C1Ro 15-1788, and ['501butanol).
The tracer concentration in arterial blood was continu ously measured to obtain the brain input function. Fol lowing image reconstruction of the scans, time-activity curves of selected regions of interest were generated. Es timations of CMRglc (1.0 ± 0.2 f,Lmol g-I min -I), CBF The development of new tracers for use in posi tron emission tomography (PET) is time-consuming and expensive. Several criteria have to be met be fore a probe can be used to study the human brain with PET (Eriksson et aI., 1990) . Apart from the obvious facts that the drug must be nontoxic and sterile, it must also pass the blood-brain barrier and have suitable uptake characteristics. Very often the in vivo behavior of the PET tracer under investiga tion may be completely unknown or the chosen (1.4 ± 0.4 ml g -I min -I) and transport rate constants for [N-methyl-"C1Ro 15-1788 (K, = 0.44 ± 0.01 ml g -1 min-I and k2 = 0.099 ± 0.005 min-I) as well as calcu lated first pass extraction (0.32 ± 0.1) are in reasonable agreement with literature values. Small animal studies re quire minimal amounts of radioactivity and can be per formed without sterility and toxicology tests. They may serve as a preliminary basis for radiation safety calcula tions because whole body scans can be performed even with a head scanner. The major advantage of this proce dure in comparison to ex vivo autoradiography is that very few experiments are necessary to reliably determine the properties of the blood-brain barrier transport of the radiotracer and the possible whole brain receptor binding characteristics. Key Words: Positron emission tomogra phy-PET tracers-PET ligand-Blood-brain barrier transport.
tracer may be a derivative of an original compound with poorly characterized in vivo behavior (Fowler and Wolf, 1986; Barrio, 1986) . Before a putative probe can be used in any experiment, the radio chemical purity must be very high. Radioactivity is lost during the purification procedure due to decay and handling. These losses and the yields in the different steps of the radiochemical synthesis limit the amount of radiotracer that can be produced. This means that an often time-consuming optimiza tion of the synthesis procedure has to be performed before it is possible to get enough radioactive tracer to perform an experiment in man. Because of the low body weight of the animal, an exploratory PET experiment in rat can be performed with < 1 % of the radioactivity required for a human experiment, as long as the specific activity of the ligand is still high enough to be considered a tracer dose.
Animal studies with autoradiographic techniques are often used to obtain anatomical data on static binding either ex vivo or by use of in vitro tech niques (d 'Argy et aI., 1987; Diksic et aI. , 1990) . If several time points are taken, data for the kinetic behavior of the compound can be estimated. This approach is very time consuming, labor intensive, and includes the assumption that the transport char acteristics are identical in all experiments on differ ent animals. Also, without a standardized injection dose and technique combined with accurate mea surements of the radioactivity in the tissue, errors may be introduced in such procedures. We present a rapid technique for obtaining kinetic data for pu tative PET tracers. The data were collected from rats with a high resolution PET scanner (Litton et aI., 1990 ) and the input function to the brain was determined by a continuous measurement of the ra dioactivity in the blood (Eriksson et aI. , 1988) 
METHODS
The procedure was approved by the regional animal ethics committee.
Experimental procedure
Male Sprague-Dawley rats weighing 20(}...4 00 g were used. The animals were allowed free access to food and water until the time of the experiments. The anesthesia began with 3.S% halothane in oxygen. The animals were tracheotomized and ventilated with a Starling type venti lator for the duration of the experiment. During the sub sequent surgical procedures the gas mixture used was 1.4-1.7% halothane in oxygen. Catheters with dimension PE SO were inserted bilaterally into femoral veins and arteries. Body temperature was monitored and kept close to 37°C. After completion of the operative procedure, the rat received 400 international units of heparin and was then placed in the PET camera. The rat's head was fixed on a horizontal plate and the position was standardized with the aid of a laser beam and thereafter shifted to the desired position in the camera.
One arterial catheter was used for obtaining intermit tent samples of -ISO !-LI that were immediately centri fuged. The concentration of radioactivity in a SO !-LI sam ple of the plasma supernatant was determined in a well counter. The venous catheter on the same side was used for injection of the radioactive tracer. On the contralat eral side the catheters were connected with a metal tube, thus creating an extracorporeal A V shunt (-4S-60 cm). This loop was placed in the detector of the automatic blood sampling system (ABSS) (Eriksson et at., 1988) and data were collected each second for S min. The shunt was then closed. The ABSS was calibrated in each experiment with the plasma concentrations that were determined in the well counter. A correction was made for the time delay between the measured arterial input function and the uptake of the tracer in the brain. The blood pressure of the animal provided the driving force for the shunt. The internal resistance of the shunt yielded a flow rate of 0.4-0.8 ml min -I (> 10% of the cardiac output). The blood taken for calibration of the ABSS was of limited amounts, and therefore did not affect the blood pressure of the animat. The rapid increase in the radioactivity in the ABSS count rate indicated that the dispersion of the blood flow in the shunt was not affecting the overall cal culations. Because the ABSS contains a pair of coinci dence detectors, the influence on the background activity was negligible even when it was placed close to the ex perimental animat.
The following tracers were tested in the procedure: FDG (synthesis see Toorongian et at., 1990) , for the determination of CMRglc (Phelps et at., 1979) . After de termination of glucose concentration in plasma (Boeh ringer Ingelheim, FRG, Glucoanalyzer), an injection of 120 !-LCi of the tracer was made. Plasma radioactivity was determined as above and also intermittent determinations of the glucose concentration in plasma were made. A con ventional PET -scanning protocol was used. The first six scans had durations of 20 s and later the scanning times were prolonged to S min.
[150]butanol (Berridge et at., 1990) , for the determina tion of CBF. P ac02 and P a02 were determined prior to the start of the experiment (100 I.d samples, Radiometer, Copenhagen). Two manual blood samples were taken in parallel with the ABSS measurement for calibration of the latter. Several determinations of CBF could be performed in the same animal using this procedure.
[N-methyl-llC]Ro IS-1788, for the labelling of cerebral benzodiazepine receptors (Ehrin et at., 1984; Halldin et at., 1988) . The arterial input function was determined continuously as described above. An in vivo displace ment was performed by the injection of 0.2S mg of unla belled drug (Comar et at., 1979; Persson et at., 1985) IS min and 40 s after the injection of 260 !-LCi (specific ac tivity >SOO Ci/mmol) of the radiotracer.
Calculations
The calibrated full time-activity curve for the arterial plasma was obtained by graphically combining data from the ABSS with the curve for the manual data from the plasma measurements (Eriksson et at., 1988; (Fig. 1) . The images were reconstructed (Vax 3S00, Digital Equipment Corp, U.S.A.) according to a standard filtered back-projection procedure. A series of images contained one blank scan, one transmission scan for at tenuation correction, and several emission scans to ob tain multiple time points for the same animat. The recon struction was done with the highest possible filter setting (close to ramp function filter) (Fig. 2) . Regions of interest (ROls) were chosen in at least two adjacent slices of the brain, and were compared with ROls of similar size out side the brain. The transaxial physical resolution of this procedure is 4.S mm full width half maximum (FWHM) and the axial resolution is S mm (cross plane) or 6 mm (direct plane). The recovery of events has been shown to be linear within the range of activity that was used in the present experiments (Litton et al., 1990) .
The CMRglc was estimated according to a three com partment kinetic model (Phelps et at., 1979) as
Time (min) where Kl is the rate constant for the unidirectional trans port of FDG from plasma to brain, and k2 and k3 are the rate constants for the return to the plasma compartment and for the phosphorylation of FDG, respectively. L is the lumped constant (the correction factor for the prefer ential use of glucose rather than deoxyglucose in the brain) (Sokoloff et aI., 1977) and Cp is the concentration of nonlabelled glucose in plasma. A lumped constant of 0.58 was used (Lear and Ackerman, 1989).
FIG. 2. A:
Brain radioactivity in a rat injected with [N-methyl11CjRo 15-1788. B: After injection of the nonradioactive ligand in the same animal no difference can be seen between radioactivity in the brain and in the surrounding soft tissue. C: A horizontal section is shown from the same rat before the displacement. The use of a high filter setting yields an ac ceptable resolution of the rat brain. The higher concentration of the tracer in the cerebrum than in the cerebellum is similar to the findings in human (Persson et aI., 1989) . No attempt to quantify this difference was made due to expected partial volume effects.
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FIG. 1. Activity in plasma as measured with the continuous blood sampling system and calibrated with intermit tent plasma samples measured in a well counter. The curve is from the same experiment as depicted in Fig. 4 where [N-methyl-11CjRo 15-1788 was used as a tracer. The difference in time between the arrival of the peak to the brain and to the detector was taken into account when the true cerebral input function was estimated.
The CBF was estimated according to the standard two compartment model and the estimation of the kinetic rate constants for [N-methyl-11C1Ro 15-1788 was performed according to standard two and three compartment models (Lassen and Perl, 1979; Blomqvist, 1984; Huang et aI., 1986 ).
RESULTS
The procedure described above allowed the re construction of a continuous curve for the estima tion of plasma or blood concentrations of the in jected substance. I An example of a plasma curve is shown in Fig. 1 .
The rate constants for the FDG were determined to be K I = 0.33 ± 0.03 ml g-I min-I, k2 = 0.76 ± 0.12 min -I, k3 = 0.14 ± 0.01 min -I, and k4 = 0.023 ± 0.03 min -I. The Akaike test favored a four parameter relative to a three-parameter solution. For the analysis, a fixed cerebral blood volume (CBV) of 4% was used. With the obtained rate con stants and the expression above the CMRglc was 1.0 ± 0.2 !-lmol g-I min -I (Fig. 3) . Borgstrom et ai. (1976) published a whole brain value of 0.70 !-lmol g-I min -I when they applied a modified kinetic measurement with radioactive glucose. Values ob tained with the auto radiographic Sokoloff technique compare reasonably well with our results (Sokoloff et aI., 1977; Ingvar et aI. , 1980) .
The CBF was calculated to be 1.4 ± 0.4 ml g-I min -I (mean ± SD in four ROls from two experi- ments). In rats where CBF was measured under light anesthesia with a modified Kety-Schmidt technique, values between 1.0 and 1.3 have been reported (Borgstrom et al. , 1974; Hagerdahl et al. , 1975) . The influence of the anesthetic procedure should be taken into account when comparing ki netic results from different studies.
In the case of [N-methyl-llC]Ro 15-1788, the brain uptake data (Fig. 4A) were analyzed accord ing to standard two-and three-compartment models with two-, three-, and four-model parameters for the incorporation phase up to the time for the dis placement (James and Roos, 1975) . The Akaike sta tistical test gave preference for a two-compartment analysis (K1 and k2' CBV set to 4%) possibly due to the limited time period used for the analysis (13 min). The results were K l = 0.44 ± 0.01 ml g� I min � I and k2 = 0.099 ± 0.005 min � I. In the exper iment, no correction for metabolism of [N-methyl l l C]Ro 15-1788 was made. The apparent distribu tion volume over time (Fig. 4B ) was calculated by use of the data from the cerebral uptake divided by the integrated arterial plasma concentration of the drug (Patlak et al., 1984) . The initial first pass ex traction was determined to be 0. 32 ± 0.1 using the relation K l = CBF*E; where E is the extraction, and the value for CBF from above was used.
It was possible to displace �90% of the brain radioactivity after a bolus injection of nonradioac tive ligand, which is consistent with published re suits (Persson et al. , 1989 ) (see Fig. 4A and B and Fig. 2) . The release of ligand from the receptor and the clearance from the brain was rapid (tl12 = 30 s).
DISCUSSION
The high cost and the risks from exposure to ion izing radiation for experimental subjects in PET studies necessitate a limitation on the number of human experiments performed during the develop ment of a new tracer. A knowledge of the kinetic properties of any suggested tracer substance is therefore a great advantage in the search for new probes for transmitter function. The procedure pre sented here provides a method for obtaining reliable in vivo kinetic information about a putative tracer very early during the design of a new PET ligand. Studies on large animals are commonly used during the development of new PET tracers (Comar et al., 1979; Aquilonius et al., 1989; Hawkins et al., 1989; Nordberg et al., 1989; Hartvig et al., 1990) . Often such procedures do not include measurement of the cerebral input function, which will limit the results of a study to a simple time-activity curve and ex clude calculation of kinetic rate constants.
One of the problems associated with PET radio chemistry is the necessary trade-off between rapid synthesis times and high radiochemical yields. Ob-taining enough radioactivity for human studies in volves optimizing both reactions and procedures for handling large amounts of radioactivity. Very often radiotracers developed for PET are derivatives of either known drugs or endogenous substances (Bar rio, 1986; Fowler and Wolf, 1986) . A minor struc tural change can sometimes yield analogs with sig nificantly different kinetic behavior in vivo (see, e.g., Lear and Ackerman, 1989) . The procedure de scribed here provides a viable method for rapidly testing the structure-activity relationships of a se ries of proposed new tracers. Also, extensive toxi cological testing of putative PET ligands in humans can be limited to the most promising tracer mole cules. The amount of radioactivity per study neces sary for ir\iection is < 1 % of a conventional human study (70 versus 0.3 kg). Thus, low yields and lengthy syntheses pose much less of a problem with this technique, with the exception of their effect on the specific activity.
The method has been validated by comparison of the values obtained for the CMRglc and CBF with corresponding values published in the literature (Borgstrom et ai., 1974 (Borgstrom et ai., , 1976 Hagerdahl et ai., 1975; Sokoloff et ai., 1977; Sakurada et ai., 1978; Ingvar et ai., 1980) . The estimation of the kinetic parameters for [N-methyl-IlC]Ro 15-1788 compares acceptably with experiments performed in humans considering the higher blood flow in the rat (Persson et ai., 1989; Holthoff et ai., 1991) . The accuracy in the estimation of the radioactivity in the brain with the present approach could be limited by the reso lution of the camera. However, the obtained values for CBF and CMRglc in the chosen ROls suggest that such errors are of limited importance. Attempts are now being made to construct special rat PET scanners (Rajeswaran et ai., 1990) . In order to offer a real advantage over the present procedure, such instruments should have a resolution of <3 mm. With suitable tracers, our procedure can be com bined with auto radiographic determinations of ra dioactivity in the same animals at the end of the PET scanning, thereby adding information about lo cal distribution of the tracer.
In vivo PET measurements have been made in rat previously by use of nontomographic external co incidence detection (Takagi 1984; Redies et ai., 1987) . Such a technique presents a problem in that the location of the radioactivity is crudely deter mined. The extracerebral fraction of radioactivity is high immediately after the injection of a tracer. This gives an error in the estimation of, for example, CBF where the basic assumption is that the calcu lation must be made from a homogeneous compart ment (Lassen and Perl, 1979 It should be emphasized that several measure ments can be performed in the same animal in ex periments of this type (Takagi et ai., 1984) . Thus, drug effects on, for example, CBF can be studied with this technique. Sometimes it is necessary to verify that a putative tracer does not affect the CBF. This is especially important when multiple injection protocols with different specific activities are used in PET. In such procedures it is very often assumed in the analysis that the rate constants for the transport across the blood-brain barrier are the same in the different experiments (Blomqvist, 1984; Huang et ai., 1986) . With the presented technique it is possible to determine if such assumptions are per missible or not.
In summary, high resolution PET technique has now been used for obtaining in vivo information on new PET tracers in small animals. This will make it possible to screen large numbers of putative tracers more rapidly. Thus it will facilitate the discovery of new ligands not previously studied in vivo.
